Diabetes trials on SGLT2 and GLP1 and their effects on hypertension - report from ESH2023

Professor Peter Nilsson held a lecture on the cardiovascular effects of SGLT-2 inhibitors and GLP-1 agonists, the two new drug classes which revolutionized the treatment of type-2 diabetes at the recent Annual Congress of the European Society of Hypertension. According to the results: - SGLT-2 inhibitors and GLP-1 receptor agonists are mostly safe, well-proven and effective drugs to prevent CVD complications and renal impairment/ events in type 2 diabetes patients at high or medium risk. - GLP-1 RAs are more effective than SGLT-2is to reduce bodyweight, but SGLT-2is are more effective than standard GLP-1 RAs to reduce office and ambulatory BP. -Recent guidelines suggest using SGLT-2i and GLP1 RA more frequently in patients at high cardiovascular risk, with or without metformin. Video: https://medicaldigest.org/scientific-contents/interview:diabetes-trials-sglt2-and-glp1-and-their-effects-hypertension